S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|ARIAD Announces Follow-up Data from Phase 1 and PACE Trials of Ponatinib in Patients with T315I Mutation in Chronic Myeloid Leukemia|
|ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib in Chronic-Phase Chronic Myeloid Leukemia from Phase 1 Clinical Trial|
|ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial|
|ARIAD and STA Announce Approval of Iclusig (Ponatinib) in Australia|
|ARIAD Announces Recommendation for Iclusig by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency|
|IBM Opens New Cloud Resiliency Center|
|ARIAD Announces Adoption of Final Opinion for Iclusig by Committee for Medicinal Products for Human Use in Europe|
|ARIAD Reports Third Quarter 2014 Financial Results and Development Progress|
|NeoGenomics is First to Offer Molecular Testing for Resistance to Bruton Tyrosin Kinase Inhibitors for Chronic Lymphocytic Leukemia|
|Preliminary Data From Ongoing Phase I/II Dose Escalation Study of TG-1101 (Ublituximab) in Combination With TGR-1202 in Heavily Pre-treated Relapsed/Refractory B-Cell Malignancies Demonstrates Encouraging Clinical Activity and Safety|
Click above to view more mutual fund data and stats for bcr - CR Bard Inc.